Original Research

Efficacy and Safety of Direct-Acting Antiviral Drugs in Hepatitis C Virus Infection Genotype-3 in South Punjab Pakistan

Qazi Masroor Ali1
Quaid-e-Azam Medical College, Bahawalpur
Ali Imran2
Bahawal Victoria Hospital Bahawalpur
Sadaf Shafique2
Bahawal Victoria Hospital Bahawalpur
Hafiz Muhammad Kaleem Ullah2
Bahawal Victoria Hospital Bahawalpur
Sajjad Sohail2
Bahawal Victoria Hospital Bahawalpur
Sohail Tariq2
Bahawal Victoria Hospital Bahawalpur
Maria Masroor3
Shaikh Zayed Hospital, Rahim Yar Khan
Ghulam Muhy-ud-Din Chaudhary4
Nishtar Medical University, Multan

✉ Correspondence: Qazi Masroor Ali Email: masroorqazi@outlook.com

DOI https://doi.org/10.70302/jpsim.v2i4.2166
Volume: 2, Issue 4 Pages: 299–303 Published: 14 Dec 2021
Received: 15 Sep 2021 Accepted: 17 Oct 2021 Published Online: 14 Dec 2021

Abstract

Objective

To find out the safety and efficacy of direct anti-viral agents for the treatment of cHCVgenotype-3 infection.

Methods

This retrospective study included record 1536 cHCVpatient who were treated at medical outpatient department (MOPD) of Medical Unit-1 of Bahawal Victoria Hospital, Bahawalpur from April 2018 to April 2020. Polymerase chain reaction (PCR) was done 3 months after completion of treatment to note sustained virologic response (SVR). Patients were compared for various demographical characteristics, laboratory findings, comorbidities, types of direct anti-viral agents (DAAs) and treatment related adverse-effects.

Results

In a total of 1536 patients, 725 (47.2%) were male and 811 (52.8%) female. Overall, mean age was noted to be
43.2+12.8 years. Overall, SVR was noted in 1447 (94.2%) patients while there was no statistically significant difference between SVR of different DAAs (p=0.0656). Significantly linked factors with No-SVR were found to be older age (46.2+12.3 vs. 43.8+10.4 years, p=0.0368), higher BMI (27.7+3.1 vs. 26.8+2.3, p=0.001), cirrhosis (49.4% vs. 8.4%, p<0.001) and non-responders/relapsers (23.6% vs. 11.5%, p=0.001). Generalized weakness was noted to be the most frequently reported on-treatment side-effect in 471 (30.7%) while body aches & pain and fever were the other most frequently reported side-effects in 230 (14.5%) and 145 (9.4%).

Conclusion

Overall sustained virologic response with various kinds of direct-acting antiviral agents for chronic hepatitis C virus infection genotype-3 was noted to be good and comparable with real world data from different parts of the world. Increasing age, higher BMI, cirrhosis and non-responders/relapsers were found to have significant association with nonachievement of SVR. Adverse-effects related to different direct anti-viral agents were few and mild in nature.

Keywords
Direct acting anti-viral agents genotype-3 hepatitis C sustained virologic response

How to Cite This Article

Ali QM, Imran A, Shafique S, Ullah HMK, Sohail S, Tariq S, et al.. Efficacy and Safety of Direct-Acting Antiviral Drugs in Hepatitis C Virus Infection Genotype-3 in South Punjab Pakistan. J Pak Soc Intern Med. 2021;2(4):299–303. doi:10.70302/jpsim.v2i4.2166

⭳ Download PDF

Conflict of Interest

All authors declare no competing interests.

Disclosed in accordance with ICMJE and COPE guidelines.

Funding

No specific funding was received for this research.

Funder information follows the Crossref Funder Registry standard.

References

  1. Butt N, Reema S, Khan MA, Abbasi A, Butt S, Masood. MK, et al. Efficacy and safety of sofosbuvir and ribavirin for treating chronic hepatitis C, genotype 3: Experience of a Tertiary Care Hospital at Karachi, Pakistan. Cureus 2019;11(4):e4458.
  2. Lavanchy D: The global burden of hepatitis C . Liver Int. 2009;1(1):74-81.
  3. Gower E, Estes C, Blach S, Shearer KR, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):45–57.
  4. Akhter TS, Umar M, Khaar H, Aslam F, Nisar G, Naseer A, et al. Sofosbuvir For The Treatment Of Hepatitis C Genotype 3 Infected Patients In Pakistan. J Ayub Med Coll Abbottabad 2016;28(4 Suppl 1):884-9.
  5. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335–74.
  6. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136(4):288–92.
  7. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002:36(5 Suppl 1):S237–44.
  8. Stanciu C, Muzica CM, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Huiban L, Chiriac S, Cuciureanu T, Trifan A. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother. 2021;22(13):1729-41.
  9. Zhuang L, Li J, Zhang Y, Ji S, Li Y, Zhao Y, et al. Real-world effectiveness of Direct-Acting Antiviral regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis. Ann Hepatol. 2021;23(3):100268.
  10. Mushtaq S, Mansoor A, Umar M, Khan A, Siddiqi S, Manzoor S. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan. J Med Virol. 2020;3(1):1-21.
  11. Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and pharmacodynamic considerations: A 2019 Update. Clin Pharmacokinet 2019;58(10):1237–63.
  12. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461–511.
  13. Hong CM, Liu CH, Su TH, Yang HC, Chen PJ, Chen YW, et al. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. J Microbiol Immunol Infect. 2020;53(4):569-577.
  14. Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY‐3+). Hepatology. 2016;63(5):1430–1441.
  15. Mushtaq S, Akhter TS, Khan A, Sohail A, Khan A, Manzoor S. Efficacy and safety of generic Sofosbuvir plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real- World outcomes from Pakistan. Front Pharmacol. 2020;11(9):550205.
  16. Merat S, Sharifi AH, Haj-Sheykholeslami A, Poustchi H, Fattahi B,Nateghi-Baygi A, et al. The Efficacy of 12 Weeks of Sofosbuvir, Da-clatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3. Hepat Mon. 2016;17(1):e44564.
  17. Abdulla M, Ali H, Nass H, Khamis J, AlQamish J. Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain. Hepat Med. 2019;11(1):69-78.
  18. Cárdaba-García ME, Abad-Lecha E, Calleja-Hernández MÁ. Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment. Libyan J Med. 2021;16(1):1949797.
  19. Benı́tez-Gutiérrez, L, Barreiro P, Labarga P, de Mendoza C, Fernandez-Montero JV, Arias A, et al. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother. 2016;17(9):1215–23.
  20. Buti M, Riveiro-Barciela M, Esteban R. Management of directacting antiviral agent failures. J Hepatol. 2015;63(6):1511–22.
  21. Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, et al. Hepatitis C virus drug resistance–associated substitutions: State of the art summary. Hepatology 2015;62(5):1623–32.

Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.

CC BY CC BY 4.0 This article is published under the Creative Commons Attribution 4.0 International License. May be shared and adapted with attribution. © 2021 Journal of Pakistan Society of Internal Medicine.
📃 In This Issue View All
Original Article Impact of Diabetes Mellitus on Post-Operative Wound Healing in General Surgery Siddiqui FA, Noor M, Akhtar W Review Article Antibiotic Resistance Patterns in Community-Acquired Pneumonia: Emerging Trends Hussain I, Farooq Z Original Article Comparison of Ultrasound-Guided versus Landmark-Based Central Venous Catheter Insertion Zafar S, Gillani SA Review Article Statin Therapy in Non-Alcoholic Fatty Liver Disease: A Systematic Review Nawaz F, Cheema HA, Mehmood Y Original Article Cervical Cancer Screening Awareness Among Rural Women in Punjab Bibi S, Anjum R, Hassan F
👥 More by These Authors
Original Article Serum Ferritin as a Prognostic Marker in COVID-19 Severity: A Hospital-Based Study Rehman N, Sheikh I, Javed K Original Article Prevalence of Hypertension Among Urban Adults in Pakistan: A Cross-Sectional Study Khan TM, Ahmed S, Malik RA Original Article Neonatal Sepsis: Bacteriological Profile and Antibiogram in a Tertiary Care Hospital Iqbal M, Rashid T Original Article Outcomes of Laparoscopic Cholecystectomy in Acute Cholecystitis: A Retrospective Analysis Raza SH, Butt N, Qureshi AM
🔗 Related Articles By Keywords
Original Article Comparison of Ultrasound-Guided versus Landmark-Based Central Venous Catheter Insertion Zafar S, Gillani SA Review Article Statin Therapy in Non-Alcoholic Fatty Liver Disease: A Systematic Review Nawaz F, Cheema HA, Mehmood Y Original Article Cervical Cancer Screening Awareness Among Rural Women in Punjab Bibi S, Anjum R, Hassan F Review Article Thyroid Disorders in Pregnancy: Clinical Implications and Management Strategies Baig BI, Usman A